Status:
UNKNOWN
Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome
Lead Sponsor:
Shaoxing Second Hospital
Conditions:
ARDS
Eligibility:
All Genders
18-90 years
Phase:
PHASE1
Brief Summary
Currently, there is no proven effective pharmacologic treatment available for patients with the acute respiratory distress syndrome (ARDS). Mesenchymal stem cells have been shown to be effective in tr...
Eligibility Criteria
Inclusion
- ARDS diagnosed using Berlin definition
- Eligible patients were at least 18 years of age had acute onset of ARDS.
- Bilateral opacities in chest radiography
- No cardiac failure
- PaO2/FiO2 ratio \< 200
Exclusion
- 72 hours after all inclusion criteria met
- Pre-existing severe diseases of any major organs
- Pregnancy
- Pulmonary hypertension
- Malignant diseases
- HIV infections.
Key Trial Info
Start Date :
November 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2014
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01902082
Start Date
November 1 2012
End Date
June 1 2014
Last Update
July 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaoxing Second Hospital
Shaoxing, Zhejiang, China, 312000